Systemic therapies for primary breast cancer have made great progress over the past two decades. However, oncologists confront an insidious and particularly difficult problem: in those patients with metastatic breast cancer, up to 50% of human epidermal growth factor 2 (HER2)-positive and 25–40% of triple-negative subtypes, brain metastases (BM) kill most of them. Fortunately, standard- of-care treatments for BM have improved rapidly, with a decline in whole brain radiation therapy and use of fractionated stereotactic radiosurgery as well as targeted therapies and immunotherapies. Meanwhile, advances in fundamental understanding of the basic biological processes of breast cancer BM (BCBM) have led to many novel experimental therapeutic strategies. In this review, we describe the most recent clinical treatment options and emerging experimental therapeutic strategies that have the potential to combat BCBM.

Original languageEnglish (US)
JournalTherapeutic Advances in Medical Oncology
StateE-pub ahead of print - Jun 30 2020


  • breast cancer brain metastasis
  • emerging treatment strategies
  • translational therapeutics

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience'. Together they form a unique fingerprint.

Cite this